Released On
August 31, 2020

Expires On
August 31, 2021

Media Type
Internet

Completion Time
90 minutes

Specialty
Psychiatry

Topic(s)
Alzheimer's, Dementia, Geriatric Medicine, Mental Health

Scroll to the Bottom of this Information to Begin this Course

This continuing medical education activity is jointly provided by the American Association for Geriatric Psychiatry and MedEdicus LLC.

This continuing medical education activity is supported through an unrestricted educational grant from ACADIA Pharmaceuticals Inc.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — 1.5 Contact Hours
  • Psychologists — 1.5 Continuing Education Credits
  • Social Workers — 1.5 Continuing Education Credits

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity intends to provide education for psychiatrists, physicians, physician assistants, nurses, social workers, and psychologists caring for patients with dementia-related psychosis (DRP).

Program Overview

Among patients with dementias (including Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, Parkinson’s disease dementia, and frontotemporal dementia), between 15% and 75% experience symptoms of psychosis. Patients with neuropsychiatric symptoms of dementia, including DRP, are at risk of adverse outcomes such as accelerated disability and mortality, lower quality of life for both patients and their caregivers, and earlier institutionalization. The root cause of symptoms of psychosis in patients with dementias should always be investigated. Management of DRP includes nonpharmacologic interventions first, followed by pharmacologic treatment when symptoms are severe, dangerous, or distressing to the patient. Some antipsychotic treatment options are safer and more effective than others, as outlined in the Beers criteria and as described in the literature and in presentations of recent clinical trial data. The desired results of this activity are for psychiatrists, physicians, physician assistants, nurses, social workers, and psychologists to recognize psychosis as part of the neurodegenerative process in dementia and to treat symptoms effectively while maintaining safety and quality of life of patients.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Apply best practices in assessment and diagnosis of DRP
  • Interpret recent clinical trial data for the treatment of DRP
  • Develop evidence-based, safe treatment plans for persons with DRP

Faculty

George T. Grossberg, MD

George T. Grossberg, MD (Chair)

Samuel W. Fordyce Professor
Director, Geriatric Psychiatry
Department of Psychiatry and Behavioral Neuroscience
Saint Louis University School of Medicine
St Louis, Missouri

Jeffrey L. Cummings, MD, ScD

Jeffrey L. Cummings, MD, ScD

Director, Chambers-Grundy Center for Transformative Neuroscience
Department of Brain Health
School of Integrated Health Sciences
University of Nevada, Las Vegas
Director Emeritus, Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada

Elaine R. Peskind, MD

Elaine R. Peskind, MD

Friends of Alzheimer’s Research Professor of Psychiatry
Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
Co-Director, VA Northwest Mental Illness Research, Education, and Clinical Center
VA Puget Sound Health Care System
Seattle, Washington

To Obtain CME/CE Credit

To obtain CME/CE credit for this activity, read the material in its entirety and consult referenced sources as necessary. Please take the post test and evaluation. Upon passing, you will receive your certificate immediately. You must score 70% or higher to receive credit for this activity, and may take the test up to 2 times. Upon registering and successfully completing the post test, your certificate will be made available online and you can print it or file it. There are no fees for participating in and receiving credit for this activity.

Physicians and Nurses:

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Association for Geriatric Psychiatry. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Successful completion of this program qualifies for up to 1.5 AMA PRA Category 1 Credits™ for physicians and 1.5 contact hours for nurses.

Psychology Education:

Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

Social Workers:

As a Jointly Accredited Organization, Amedco is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Amedco maintains responsibility for this course. Social workers completing this course receive 1.5 continuing education credits.

Grantor Statement

This continuing medical education activity is supported through an unrestricted educational grant from ACADIA Pharmaceuticals Inc.

Disclosures

Jeffrey L. Cummings, MD, ScD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of

  • Stock Shareholder: Adamas Pharmaceuticals, Inc; Annovis Bio; Bioasis Technologies, Inc; MedAvante-ProPhase, Inc; and United Neuroscience
  • Consultant: ACADIA Pharmaceuticals Inc; Actinogen; AgeneBio, Inc; Alkahest, Inc; Alzheon, Inc; Annovis Bio; Avanir Pharmaceuticals, Inc; Axsome Therapeutics, Inc; Biogen Idec; Cassava Sciences, Inc; Cerecin Inc; Cerevel Therapeutics, LLC; Cognoptix Inc; Cortexyme; EIP Pharma, Inc; Eisai Inc; F. Hoffmann-La Roche Ltd; Foresight; Green Valley Inc; Grifols; Hisun USA, Inc; Idorsia Pharmaceuticals Ltd; Karuna Therapeutics; Nutricia; Orion Corporation; Otsuka America Pharmaceutical, Inc; ReMYND; Resverlogix; Samumed, LLC; Samus Therapeutics, Inc; Third Rock Ventures; Signant Health; Sunovion Pharmaceuticals Inc; Suven Life Sciences Limited; United Neuroscience; and Vivoryon Therapeutics AG
  • Other Financial or Material Support: CNS Innovations LLC

He reports Spouse financial agreement or affiliations as follows:

  • Ownership Interest: CNS Innovations LLC

George T. Grossberg, MD had a financial agreement or affiliation during the past year with the following commercial interests in the form of

  • Research Grant Site Principal Investigator: F. Hoffmann-La Roche Ltd; and Janssen Global Services, LLC
  • Consultant: ACADIA Pharmaceuticals Inc; Alkahest, Inc; Avanir Pharmaceuticals, Inc; BioXcel Therapeutics; H. Lundbeck A/S; Otsuka America Pharmaceutical, Inc; and Takeda Pharmaceuticals USA, Inc
  • Other Financial or Material Support (Safety Monitoring Committee): EryDel SPA; and Newron Pharmaceuticals SPA

Elaine R. Peskind, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of

  • Research Grant Site Principal Investigator: Eli Lilly and Company
  • Stock Shareholder: Bristol-Myers Squibb Company
  • Scientific/Medical Advisory Board Member: ACADIA Pharmaceuticals Inc; and Avanir Pharmaceuticals, Inc

Editorial Support Disclosures

Kristin Bundy; Erika Langsfeld, PhD; Cynthia Tornallyay, RD, MBA, CHCP; and Michelle Ong have no relevant commercial relationships to disclose.

Disclosure Attestation

The contributing physicians listed above have attested to the following:

  1. that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity
  2. that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
  3. that all reasonable clinical alternatives will be discussed when making practice recommendations.

Off-Label Discussion

This educational activity might contain discussion of evidence-based and/or investigational uses of agents that are not indicated by the FDA. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the official prescribing information for each product.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the American Association for Geriatric Psychiatry, MedEdicus LLC, or ACADIA Pharmaceuticals Inc.

This CME/CE activity is copyrighted to MedEdicus LLC © 2020. 216